Patricia Valerio, PhD,  science writer—

Patricia holds a PhD in Neurobiology from the University of Basel, Switzerland, where she studied how hearing develops and functions. She is originally from Portugal and earned an MSc in Cellular and Molecular Biology, focusing on metabolic diseases, such as diabetes, and a BSc in Biomedical Pharmacy from the University of Coimbra. Patricia enjoys communicating science to inspire, educate and help different audiences understand its complexity and relevance.

Articles by Patricia Valerio

FDA names RAG-17, targeting ALS gene mutations, an orphan drug

RAG-17, an investigational therapy from Ractigen Therapeutics to treat amyotrophic lateral sclerosis (ALS), has been designated an orphan drug by the U.S. Food and Drug Administration (FDA). Orphan drug status is given to medicines intended to treat life-threatening or chronically debilitating diseases that affect fewer than 200,000 individuals…